ZHENGYI WANG1,*, LIANG ZHOU1, XIAOYING WU2
Oncology Research, Vol.32, No.9, pp. 1479-1516, 2024, DOI:10.32604/or.2024.048564
Abstract Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread More >
Graphic Abstract
Login
Register
